Skip to main content
Year archive

Camurus — 2019 filings

All 45 regulatory filings released by Camurus (CAMX) in 2019, sourced directly from the official regulator.

45 Filings
2019 Period
2019 filings (45)
Filing Released Lang
Förändring av antalet aktier och röster i Camurus
Share Issue/Capital Change
2019-12-30 Swedish
Change in number of shares and votes in Camurus
Declaration of Voting Results & Voting Rights Announcements
2019-12-30 English
Camurus has completed a directed share issue of approximately 3.7 million shares, raising proceeds of approximately 300 MSEK
Share Issue/Capital Change
2019-12-09 English
Camurus har genomfört en riktad nyemission om cirka 3,7 miljoner aktier och tillförs härigenom cirka 300 MSEK
Share Issue/Capital Change
2019-12-09 Swedish
Camurus meddelar signifikant förbättrade behandlingsresultat för Buvidal[®] jämfört med standardbehandling i ny klinisk studie
Regulatory Filings
2019-11-26 Swedish
Camurus announces new study results showing superior patient reported outcomes with Buvidal[®] versus standard of care in treatment of opioid dependence
Environmental & Social Information
2019-11-26 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q3 2019
2019-11-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q3 2019
2019-11-08 English
Camurus meddelar att FDA bifaller Braeburns Citizen Petition och eliminerar risken för ytterligare blockering av Brixadi™ i USA
Legal Proceedings Report
2019-11-08 Swedish
Camurus announces that FDA grants Braeburn’s Citizen Petition, eliminating the risk of further blocking of Brixadi™ from the US market
Legal Proceedings Report
2019-11-08 English
Camurus’ Nomination Committee appointed for the Annual General Meeting 2020
Board/Management Information
2019-10-15 English
Valberedning utsedd inför Camurus årsstämma 2020
Board/Management Information
2019-10-15 Swedish
Camurus announces positive outcome of US court proceeding about final approval of Brixadi™
Legal Proceedings Report
2019-07-23 English
Camurus meddelar positivt utfall i amerikansk rättsprocess om marknadsgodkännande av Brixadi™
Legal Proceedings Report
2019-07-23 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-07-18 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-07-18 English
Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
Regulatory Filings
2019-07-16 English
Camurus och Ra Pharma ingår licensavtal för långtidsverkande zilucoplan
Regulatory Filings
2019-07-16 Swedish
Camurus meddelar att FDA beviljar fas 3-studie av CAM2029 för behandling av akromegali
Regulatory Filings
2019-06-20 Swedish
Camurus receives IND acceptance from the FDA to enter Phase 3 with CAM2029 for treatment of acromegaly
Regulatory Filings
2019-06-20 English
Resolutions at the annual general meeting 2019 in Camurus
AGM Information
2019-05-09 English
Beslut vid Camurus årsstämma 2019
AGM Information
2019-05-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-09 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-05-09 English
Annual Report 2018
Annual Report FY 2018
2019-04-15 English
Annual Report 2018
Annual Report FY 2018
2019-04-15 Swedish
Braeburn initiates court proceedings to overturn exclusivity and seeks immediate market approval of Brixadi™ in the US
Legal Proceedings Report
2019-04-09 English
Braeburn inleder rättsprocess för att få exklusivitet upphävd och begär omedelbart marknadsgodkännande för Brixadi™ i USA
Legal Proceedings Report
2019-04-09 Swedish
Kallelse till årsstämma 2019 i Camurus AB (publ)
AGM Information
2019-04-05 Swedish
Notice of annual general meeting 2019 in Camurus AB (publ)
AGM Information
2019-04-05 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-04-02 English
Förändring av antalet aktier och röster i Camurus
Share Issue/Capital Change
2019-03-29 Swedish
Change in number of shares and votes in Camurus
Share Issue/Capital Change
2019-03-29 English
Camurus offentliggör prospekt avseende företrädesemissionen
Capital/Financing Update
2019-03-08 Swedish
Camurus publishes prospectus relating to the rights issue
Capital/Financing Update
2019-03-08 English
Resolutions at the Extraordinary General Meeting in Camurus
Capital/Financing Update
2019-03-05 English
Beslut vid Camurus extra bolagsstämma
Capital/Financing Update
2019-03-05 Swedish
Camurus announces the terms of its rights issue
Capital/Financing Update
2019-02-28 English
Camurus offentliggör villkoren för företrädesemissionen
Capital/Financing Update
2019-02-28 Swedish
Earnings Release 2018
Earnings Release Q4 2018
2019-02-06 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report FY 2018
2019-02-06 English
Camurus to progress commercialization of Buvidal and advance pipeline programs through a fully underwritten rights issue of SEK 400 million
Capital/Financing Update
2019-02-06 English
Camurus fortsätter kommersialisering av Buvidal och utveckling av läkemedelskandidater genom en fullt garanterad företrädesemission om 400 MSEK
Capital/Financing Update
2019-02-06 Swedish
Buvidal® launched as the first long-acting opioid dependence treatment in the EU
Regulatory Filings
2019-01-11 English
Buvidal® lanserad som första långtidsverkande behandlingen mot opioidberoende i EU
Regulatory Filings
2019-01-11 Swedish